Precision Biosciences (DTIL) Net Income towards Common Stockholders (QoQ) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Precision Biosciences | 171.70 Mn | 70.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -164.85% |
| Dec 31, 2025 | 164.66% |
| Sep 30, 2025 | 5.29% |
| Jun 30, 2025 | 0.11% |
| Mar 31, 2025 | 10.95% |
| Dec 31, 2024 | -20.11% |
| Sep 30, 2024 | -177.74% |
| Jun 30, 2024 | 920.82% |
| Mar 31, 2024 | -8.51% |
| Dec 31, 2023 | -170.83% |
| Sep 30, 2023 | 145.51% |
| Jun 30, 2023 | 20.27% |
| Mar 31, 2023 | -22.61% |
| Dec 31, 2022 | -9.76% |
| Sep 30, 2022 | 72.05% |
| Jun 30, 2022 | -8.58% |
| Mar 31, 2022 | 11.42% |
| Dec 31, 2021 | -165.85% |
| Sep 30, 2021 | -153.35% |
| Jun 30, 2021 | 215.88% |
| Mar 31, 2021 | 20.31% |
| Dec 31, 2020 | 9.85% |
| Sep 30, 2020 | 20.44% |
| Jun 30, 2020 | -21.85% |
| Mar 31, 2020 | -28.30% |
| Dec 31, 2019 | -0.84% |
| Sep 30, 2019 | 7.34% |
| Jun 30, 2019 | -17.36% |
| Mar 31, 2019 | -23.52% |
| Dec 31, 2018 | -58.29% |
| Sep 30, 2018 | 17.50% |
| Jun 30, 2018 | -31.23% |